Physician profile
Thomas C Roberts
NPI 1568429686
$1,441.52
in general payments reported to CMS, 2019-2025
15 companies · $177 in 2025
The $177 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43.12 · 2020: $27.84 · 2021: $101 · 2022: $301 · 2023: $301 · 2024: $491 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $968.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $968.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $432.07 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $365.31 | 2021-2025 | Mavyret, Vraylar |
| Gilead Sciences, INC. | $148.14 | 2022-2023 | |
| Indivior INC. | $82.02 | 2022-2025 | Sublocade |
| Alkermes, INC. | $78.61 | 2019-2023 | Vivitrol |
| Greenwich Biosciences, INC. | $59.72 | 2021 | |
| Dexcom, INC. | $51.63 | 2022-2023 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $39.88 | 2019-2022 | |
| Exact Sciences Corporation | $39.39 | 2023 | Cologuard Collection Kit |
| Abbott Laboratories | $35.57 | 2022 | |
| Merck Sharp & Dohme LLC | $34.19 | 2022-2024 | Vaxneuvance, Rotateq, Proquad |
| Lilly USA, LLC | $24.92 | 2019-2023 | Mounjaro |
| Neurelis, INC. | $20.62 | 2022 | |
| Novo Nordisk INC | $16.37 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.08 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.